Navigation Links
TorreyPines Therapeutics Reports Fourth Quarter and Full Year 2008 Results
Date:3/27/2009

LA JOLLA, Calif., March 27 /PRNewswire/ -- TorreyPines Therapeutics, Inc. (Nasdaq: TPTX) today announced financial results for the fourth quarter and year ended December 31, 2008. For the full year 2008, the Company posted revenue of $6.1 million and a net loss of $22.8 million. Cash and cash equivalents totaled $10.9 million at December 31, 2008.

On March 27, the Company filed with the SEC its Annual Report on Form 10-K, which included an audit opinion with a "going concern" explanatory paragraph. The going-concern explanatory paragraph from TorreyPines' independent registered public accounting firm expressed substantial doubt, based upon current financial resources, as to whether TorreyPines can continue to meet its obligations beyond 2009 without access to additional working capital. The Company discusses this matter, including its plans to address future financing needs, in its Annual Report on Form 10-K.

Financial Results

Revenue for the three-month period ended December 31, 2008, was $1.6 million, compared to revenue of $2.5 million for the same period in 2007. Operating expenses for the quarter ended December 31, 2008, were $7.8 million, with $3.2 million attributable to research and development, $1.5 million attributable to general and administrative expense and $3.1 million attributable to a loss on impairment of purchased patents. This compares to operating expenses of $9.0 million, with research and development expenses of $7.6 million and $1.4 million attributable to general and administrative expense for the same period last year. The Company reported a net loss for the quarter ended December 31, 2008, of $6.0 million, compared to a net loss of $8.2 million for the same period last year.

Revenue for the full year ended December 31, 2008, was $6.1 millio
'/>"/>

SOURCE TorreyPines Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. TorreyPines Therapeutics to Present at the NewsMakers in the Biotech Industry Conference
2. TorreyPines Therapeutics to Present at ThinkEquitys G5 Conference
3. TorreyPines Therapeutics and Eisai Co., Ltd. Extend Genetics Discovery Collaboration for Alzheimers Disease
4. TorreyPines Therapeutics to Present at ThinkEquitys ThinkClinic Conference
5. TorreyPines Therapeutics to Present at Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
6. TorreyPines Therapeutics Reports Third Quarter 2007 Results
7. TorreyPines Therapeutics to Present at Susquehanna Financial Groups Second Annual SIGnificant Options in Healthcare Conference
8. TorreyPines Therapeutics Initiates Phase II Study of Muscarinic Agonist NGX267 for Treatment of Xerostomia
9. TorreyPines Therapeutics Reports Fourth Quarter and Full Year 2007 Financial Results and Highlights
10. TorreyPines Therapeutics to Host First Quarter 2008 Results Conference Call and Webcast
11. TorreyPines Therapeutics to Present Tezampanel Phase IIb Clinical Data for Acute Migraine at 50th Annual Scientific Meeting of the American Headache Society
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... OMICS Group’s 5th International conference and exhibition ... at Double Tree by Hilton Beijing, China is all ... & Bioanalytical research methods only to facilitate improved living ... Dr. Srinubabu Gedela, MD of OMICS Group Inc has ... one in bringing a unique and international mix of ...
(Date:7/10/2014)... (PRWEB) July 10, 2014 Senior supply ... and professional associations, addressed the challenges of “Reducing Cost, ... Device Industries” through strategic sourcing. Describing the partnership of ... the Supply Chain Management Institute ( SCMI) of ... on June 24 at the Kroc Institute of Peace ...
(Date:7/10/2014)... 10, 2014 On July 9 ... , presented Russia,s first national ... The Company is developing a unique project called ... develops a number of innovative drugs based on monoclonal ... ceremony took place at the International Exhibition "Innoprom 2014" ...
(Date:7/10/2014)... 2014 /PRNewswire-iReach/ -- Tute Genomics, the leader ... an agreement with Lineagen, Inc., to provide ... Dx PLUS.  Lineagen, focused on the ... currently offers FirstStep Dx PLUS, a ... by healthcare providers as a first-line genetic ...
Breaking Biology Technology:A Critical Review of Analytical Techniques for Improved Living Standards 2A Critical Review of Analytical Techniques for Improved Living Standards 3A Critical Review of Analytical Techniques for Improved Living Standards 4Biotech & Biopharm Supply Chain Management Executives Launch BSMA in San Diego 2Biotech & Biopharm Supply Chain Management Executives Launch BSMA in San Diego 3Biotech & Biopharm Supply Chain Management Executives Launch BSMA in San Diego 4Dmitry Medvedev Presented BIOCAD the First National "Industry" Award 2Tute Genomics Platform Selected to Provide Clinical Interpretation for Lineagen's NextStepDx PLUS Next-Generation Sequencing-Based Diagnostic Test 2Tute Genomics Platform Selected to Provide Clinical Interpretation for Lineagen's NextStepDx PLUS Next-Generation Sequencing-Based Diagnostic Test 3Tute Genomics Platform Selected to Provide Clinical Interpretation for Lineagen's NextStepDx PLUS Next-Generation Sequencing-Based Diagnostic Test 4
... SAN CARLOS, Calif., May 22 Nektar,Therapeutics (Nasdaq: ... Ph.D.,J.D. has joined the Company as Chief Operating ... responsibilities include overseeing and,managing all aspects of the ... as operations across the Company. He will also,serve ...
... Celldex,Therapeutics (a wholly-owned subsidiary of AVANT,Immunotherapeutics)(Nasdaq: AVAN ... being developed for the treatment of Glioblastoma,Multiforme (GBM), ... at the 44th,Annual Meeting of the American Society ... held at McCormick Place in Chicago from May ...
... DRAD ), a leading provider of medical ... and imaging centers, today,announced the signing of a ... Medicine in Baltimore, Md., Under terms of ... read,diagnostic images for primary care physicians, throughout the ...
Cached Biology Technology:Bharatt Chowrira Joins Nektar Therapeutics as Chief Operating Officer and Head of PEGylation Business Unit 2Bharatt Chowrira Joins Nektar Therapeutics as Chief Operating Officer and Head of PEGylation Business Unit 3AVANT Immunotherapeutics Announces Oral Presentation of CDX-110 at ASCO Annual Meeting 2AVANT Immunotherapeutics Announces Oral Presentation of CDX-110 at ASCO Annual Meeting 3Digirad Corporation Signs Letter of Understanding With Johns Hopkins University School of Medicine 2Digirad Corporation Signs Letter of Understanding With Johns Hopkins University School of Medicine 3Digirad Corporation Signs Letter of Understanding With Johns Hopkins University School of Medicine 4
(Date:7/11/2014)... the City of Entiat on Tuesday, July 8, 2014. ... grew to over 1,000 acres by evening. Three outbuildings ... investigation by the Washington Department of Natural Resources. The ... in developing fire control strategies and tactics. Other cooperators ... of Natural Resources, (WA DNR), Bureau of Land Management, ...
(Date:7/11/2014)... German . ... refraction of X-rays through a specimen instead of attenuation ... are often of much higher quality than those based ... Franz Pfeiffer are particularly interested in developing new approaches ... phase-contrast imaging. One main goal is to make this ...
(Date:7/11/2014)... from The Chinese University of Hong Kong, BGI and ... linked to salt tolerance, with implication for improving this ... published online in Nature Communications provides an ... improvement. , Soybean is an important crop for the ... have less genetic diversities than their wild counterparts. Among ...
Breaking Biology News(10 mins):New simple setup for X-ray phase contrast 2BGI reports a novel gene for salt tolerance found in wild soybean 2
... than a century ago, a brilliant young chemist and ... her ground-breaking discoveries in radioactivity. Emma Martn ... is carrying on Curie,s spirit of trail-blazing scientific inquiry, ... name. Last summer, Martn Rodrguez was one of ...
... the University of Adelaide are a promising step ... transfusions for preterm babies, by reducing the likelihood of adverse ... the most common medical procedures experienced by preterm babies, who ... the University of Adelaide,s Robinson Institute studied 28 ...
... Nov. 26, 2012 Medbox, Inc. (OTC Markets: MDBX) ... biometric medical marijuana dispensing system has arrived in Massachusetts ... to cannabis-based health care products. The two ... large, show the process of how the Medbox (Medicine ...
Cached Biology News:Following in Marie Curie's footsteps 2Better blood transfusions for preterm babies 2Medbox, Inc. Releases Demo Video and Collateral Media Concerning How Their Systems Will Be Used in Massachusetts Medical Marijuana Dispensaries 2
The iEMS Incubator/Shaker is a high performance microplate incubator and orbital shaker. Its superior temperature control and efficient orbital shaking reduce incubation times. It can incubate up to ...
... modified nucleotide structure called a ?cap? ... most naturally-occurring eukaryotic mRNAs and many ... for a portion of the GTP ... reaction results in the synthesis of ...
... nucleotide structure called a ?cap? is ... naturally-occurring eukaryotic mRNAs and many viral ... a portion of the GTP present ... results in the synthesis of transcripts ...
This Dedicated 18" X 18" (45.7 X 45.7 cm.) shaker platforms are optimized for a particular flask clip size. Dedicated platforms come fully loaded with flask clips....
Biology Products: